Literature DB >> 24020919

Unmet quality indicators for metastatic cancer patients admitted to intensive care unit in the last two weeks of life.

Jennifer A Blechman1, Norman Rizk, Marguerite M Stevens, Vyjeyanthi S Periyakoil.   

Abstract

BACKGROUND: The majority of U.S. cancer patients express the desire to die at home, though most do not, and are often subjected to ineffective therapies near the end of life (EOL). In 2008 the U.K. Department of Health and National Health Care Service implemented a set of 10 quality markers to improve EOL care (EOLC) for seriously ill persons. Data show that this intervention has had a positive impact on patients' EOLC.
PURPOSE: The study assessed the quality of EOLC received by terminally ill cancer patients admitted to the intensive care unit (ICU) in the last two weeks of life.
DESIGN: A retrospective chart review was done of the electronic medical record (EMR) of 2498 patients admitted to the ICU from January to August 2011. The six U.K. quality indicators pertaining to patients were used to assess quality of EOLC.
SETTING: The setting was a tertiary academic medical center with 663 beds and 66 adult ICU beds in northern California. PATIENTS: EMR analysis identified 2498 patients admitted to the ICU during the study period--232 died within two weeks of admission. Sixty-nine decedents had metastatic cancer. Of the patients, 58% were male, average age 59.8 years (range 25-91).
RESULTS: Quality indicators were met in a relatively small percentage of patients admitted to the ICU in the last two weeks of life: prognostication 67%, advance care planning 32%, goals of care 42%, caregiver needs 0%, coordination of care across organizational boundaries 7%, and standardized care pathway implementation 58%. Palliative care consultations occurred in 28 patients.
CONCLUSIONS: Quality indicators for EOLC were unmet in cancer patients admitted to the ICU in the last two weeks of life. Hospital-wide provider education about the need for early advance care planning with all seriously ill patients has been implemented in an effort to improve quality of care at EOL.

Entities:  

Mesh:

Year:  2013        PMID: 24020919      PMCID: PMC3791052          DOI: 10.1089/jpm.2013.0257

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  11 in total

1.  The POLST (Physician Orders for Life-Sustaining Treatment) paradigm to improve end-of-life care: potential state legal barriers to implementation.

Authors:  Susan E Hickman; Charles P Sabatino; Alvin H Moss; Jessica Wehrle Nester
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

2.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

3.  Assessment of factors influencing preservation of dignity at life's end: creation and the cross-cultural validation of the preservation of dignity card-sort tool.

Authors:  Vyjeyanthi S Periyakoil; Arthur M Noda; Helena Chmura Kraemer
Journal:  J Palliat Med       Date:  2010-05       Impact factor: 2.947

4.  Place of care in advanced cancer: a qualitative systematic literature review of patient preferences.

Authors:  I J Higginson; G J Sen-Gupta
Journal:  J Palliat Med       Date:  2000       Impact factor: 2.947

5.  England's approach to improving end-of-life care: a strategy for honoring patients' choices.

Authors:  Bradford H Gray
Journal:  Issue Brief (Commonw Fund)       Date:  2011-07

6.  Actual and preferred place of death of cancer patients. Results from the Italian survey of the dying of cancer (ISDOC).

Authors:  Monica Beccaro; Massimo Costantini; Paolo Giorgi Rossi; Guido Miccinesi; Maria Grimaldi; Paolo Bruzzi
Journal:  J Epidemiol Community Health       Date:  2006-05       Impact factor: 3.710

7.  Prognostic significance of the "surprise" question in cancer patients.

Authors:  Alvin H Moss; June R Lunney; Stacey Culp; Miklos Auber; Sobha Kurian; John Rogers; Joshua Dower; Jame Abraham
Journal:  J Palliat Med       Date:  2010-07       Impact factor: 2.947

8.  Multicultural long-term care nurses’ perceptions of factors influencing patient dignity at the end of life.

Authors:  Vyjeyanthi S Periyakoil; Marguerite Stevens; Helena Kraemer
Journal:  J Am Geriatr Soc       Date:  2013-03       Impact factor: 5.562

9.  Creation and the empirical validation of the dignity card-sort tool to assess factors influencing erosion of dignity at life's end.

Authors:  Vyjeyanthi S Periyakoil; Helena Chmura Kraemer; Arthur Noda
Journal:  J Palliat Med       Date:  2009-12       Impact factor: 2.947

10.  Terminal cancer care and patients' preference for place of death: a prospective study.

Authors:  J Townsend; A O Frank; D Fermont; S Dyer; O Karran; A Walgrove; M Piper
Journal:  BMJ       Date:  1990-09-01
View more
  4 in total

1.  Interdisciplinary Communication: Documentation of Advance Care Planning and End-of-Life Care in Adolescents and Young Adults With Cancer.

Authors:  Anne Watson; Meaghann Weaver; Shana Jacobs; Maureen E Lyon
Journal:  J Hosp Palliat Nurs       Date:  2019-06       Impact factor: 1.918

2.  Advance directives and intensity of care delivered to hospitalized older adults at the end-of-life.

Authors:  Marsha H Tyacke; Jill L Guttormson; Mauricio Garnier-Villarreal; Kathryn Schroeter; Wendy Peltier
Journal:  Heart Lung       Date:  2019-09-03       Impact factor: 2.210

3.  Do unto others: doctors' personal end-of-life resuscitation preferences and their attitudes toward advance directives.

Authors:  Vyjeyanthi S Periyakoil; Eric Neri; Ann Fong; Helena Kraemer
Journal:  PLoS One       Date:  2014-05-28       Impact factor: 3.240

Review 4.  Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review.

Authors:  Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton
Journal:  J Pain Symptom Manage       Date:  2019-10-19       Impact factor: 3.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.